Tandem CD20-CD19-Directed Non-Cryopreserved CAR T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma - Interim Results from a Phase 2 Pivotal Study (DALY II USA)

耐火材料(行星科学) 医学 弥漫性大B细胞淋巴瘤 临时的 低温保存 中期分析 CD19 CD20 淋巴瘤 内科学 临床试验 材料科学 生物 胚胎 考古 外周血 复合材料 历史 细胞生物学
作者
Nirav Niranjan Shah,Richard Thomas Maziarz,Caron Alyce Jacobson,Patrick B. Johnston,Sunil Abhyankar,Iris Isufi,Miguel‐Angel Perales,Monalisa Gosh,Matthew L. Ulrickson,Allison Claire Rosenthal,Javier Muñoz,Nancy M. Hardy,Aaron P. Rapoport,Reem Karmali,Farrukh Tauseef Awan,Matthew Stuart McKinney,Mitchell E. Horwitz,Matthew Alexander Lunning,Nathan Denlinger,Marek Ancukiewicz
出处
期刊:Biology of Blood and Marrow Transplantation [Elsevier BV]
卷期号:31 (2): S34-S34 被引量:2
标识
DOI:10.1016/j.jtct.2025.01.046
摘要

Background Zamto-cel is an investigational autologous tandem CD20-CD19-directed non-cryopreserved CAR-T cell product for patients (pts) with relapsed/refractory diffuse large b cell lymphoma (r/r DLBCL) in the DALY II USA clinical trial (NCT04792489), a multicenter, open label, single-arm Phase 2 study. Here, we report efficacy and safety outcomes as part of a pre-planned interim analysis. Methods Eligible adults had r/r DLBCL after at least 2 prior lines of treatment and measurable disease per Lugano 2014 classification. Zamto-cel was manufactured utilizing CliniMACS Prodigy® (Miltenyi Biotec), a closed, automated system with a 14-day vein-to -vein time. The primary endpoint was overall response rate (ORR) defined as best overall response (BOR) of either complete response (CR) or partial response (PR). Secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), safety, and CD19 and CD20 antigen expression at relapse. Results As of March 29, 2024, 69 pts received zamto-cel of which 59 were evaluable having received a fresh, conforming product and completed a minimum of 3 months follow-up. Median age was 63 years (range 25-85), 39 (66%) were male. The majority of pts presented with high risk factors including elevated LDH at study entry (53%), and 49% had ≥ 2 extranodal lesions. Successful manufacturing of a fresh, in specification product occurred in 91.3% out of 69 treated pts. No patient died or withdrew during the manufacturing process. The ORR in the evaluable patient population (n=59) was 72.9% (95% CI, 59.7-83.6), with a CRR of 49.2% (95% CI,35.9-62.5). The 6 month and 12 month-PFS was 55% (95%CI, 41-67) and 42% (95%CI, 28-56), respectively; 12 month-OS was 72% (95%CI, 57-83) (Fig.1). The median DOR was 11.4 months (Fig. 2). All 69 treated pts were assessed for safety outcomes. Thirty-two pts (46.4%) experienced cytokine release syndrome (CRS), all grade 1-2. Immune effector cell-associated neurotoxicity syndrome (ICANS) was reported in 12 pts (17.4%), grade 1-2 (9 pts; 13.1%); grade 3 (3 pts; 4.3%) (Fig.3). One patient experienced immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), which resolved after 2 days. Biopsies at progression were available in 24 pts. Only one patient experienced loss of both antigens compared to pre-treatment status, demonstrating maintenance of target antigen expression at relapse. Conclusion This pre-planned interim analysis represents the first pivotal trial of a tandem CD20-CD19 directed non-cryopreserved CAR-T cell product for patients with third-line r/r DLBCL. The results show encouraging activity and a favorable safety profile. Unlike currently registered CAR-T cell products, zamto-cel is administered as a fresh product with a short vein-to-vein time with a high manufacturing success rate.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
dabai发布了新的文献求助20
刚刚
科研通AI65的应助被胡123456789采纳,获得10
刚刚
苹果枫叶完成签到,获得积分10
刚刚
风雨烟城发布了新的文献求助10
刚刚
1秒前
柯夫子完成签到,获得积分10
1秒前
1秒前
dan完成签到,获得积分10
1秒前
无极微光的应助被风清扬采纳,获得20
1秒前
Ha完成签到,获得积分10
2秒前
熊猫完成签到,获得积分10
2秒前
2秒前
小鹿完成签到,获得积分10
2秒前
jiang发布了新的文献求助10
2秒前
111完成签到,获得积分20
3秒前
自信雪冥发布了新的文献求助10
3秒前
3秒前
3秒前
HTT完成签到,获得积分20
3秒前
呼呼完成签到,获得积分10
4秒前
4秒前
4秒前
yan完成签到,获得积分10
4秒前
科研通AI65的应助被蘅芷清芬采纳,获得10
4秒前
4秒前
666plus发布了新的文献求助20
5秒前
cyz完成签到 ,获得积分10
5秒前
5秒前
够顺完成签到,获得积分10
5秒前
刘震完成签到,获得积分10
6秒前
磷钼酸奎琳完成签到,获得积分10
6秒前
haha完成签到,获得积分10
6秒前
WUHAO发布了新的文献求助10
6秒前
7秒前
QDU的应助被回星予你采纳,获得10
7秒前
7秒前
7秒前
荷序发布了新的文献求助10
7秒前
DDD完成签到 ,获得积分10
7秒前
zzy完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105